Cargando…
Identification of HSP90 inhibitors as a novel class of senolytics
Aging is the main risk factor for many chronic degenerative diseases and cancer. Increased senescent cell burden in various tissues is a major contributor to aging and age-related diseases. Recently, a new class of drugs termed senolytics were demonstrated to extending healthspan, reducing frailty a...
Autores principales: | Fuhrmann-Stroissnigg, Heike, Ling, Yuan Yuan, Zhao, Jing, McGowan, Sara J., Zhu, Yi, Brooks, Robert W., Grassi, Diego, Gregg, Siobhan Q., Stripay, Jennifer L., Dorronsoro, Akaitz, Corbo, Lana, Tang, Priscilla, Bukata, Christina, Ring, Nadja, Giacca, Mauro, Li, Xuesen, Tchkonia, Tamara, Kirkland, James L., Niedernhofer, Laura J., Robbins, Paul D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583353/ https://www.ncbi.nlm.nih.gov/pubmed/28871086 http://dx.doi.org/10.1038/s41467-017-00314-z |
Ejemplares similares
-
The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs
por: Zhu, Yi, et al.
Publicado: (2015) -
Identification of a novel senolytic agent, navitoclax, targeting the Bcl‐2 family of anti‐apoptotic factors
por: Zhu, Yi, et al.
Publicado: (2016) -
Senolytic drugs: from discovery to translation
por: Kirkland, J. L., et al.
Publicado: (2020) -
Senolytics: Potential for Alleviating Diabetes and Its Complications
por: Palmer, Allyson K, et al.
Publicado: (2021) -
New agents that target senescent cells: the flavone, fisetin, and the BCL-X(L) inhibitors, A1331852 and A1155463
por: Zhu, Yi, et al.
Publicado: (2017)